Search
for
Sort by
Research 211–240 of 230
- Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- 689 Cell-type-specific nascent transcriptomics through PRECISE-seq reveal molecular principles of tissue dynamics
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs
- Targeted immunotherapy for hair regrowth and regeneration
- Advances in the mechanism and new therapies of alopecia areata
- An Updated in the Management of Alopecia Areata
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Referee report. For: Molecular mediators involved in skin healing: a narrative review [version 1; peer review: 1 approved with reservations]
- Editor's evaluation: Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Biologics in the management of childhood atopic dermatitis
- Update From Dermatology Nurses’ Association Convention 2025
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
- Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Discoid lupus erythematosus successfully treated with deucravacitinib
- A review of Janus kinase inhibitor use in scarring alopecia
- Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial